Commercial Credit Report for Cleo Diagnostics Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Cleo Diagnostics Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Cleo Diagnostics Ltd
480 Collins Street, Level 2
Phone: +61 396140600p:+61 396140600	Melbourne, VIC 3000 Australia	Ticker: COVCOV

Business Summary

Cleo Diagnostics Ltd is an Australia-based medical diagnostics company. The Company is focussed on the development of non-invasive blood based In vitro diagnostics (IVD) tests to detect the presence, and recurrence, of ovarian cancer. The Company has developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant. Recurrence Test is a post-surgical test to identify whether a cancer is recurring following surgical removal and chemotherapy of a primary tumour. Screening Test is a screening test to identify early-stage ovarian cancer in women who do not present any symptoms consistent with ovarian cancer. The Company also offers the CLEO Test Kit, which is designed to detect a novel protein biomarker, CXCL10 in the blood.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	6/30/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8071	Medical laboratories
2835	In vitro and in vivo diagnostic substances

Officers and Directors

Title	Name	Age	Title Date	Start Date
Non-Executive Chairman of the Board	Adrien M.Wing		8/11/2022	8/11/2022
Chief Executive Officer, Executive Director	RichardAllman	57	10/10/2022	10/10/2022
Chief Scientific Officer, Executive Director	Andrew N.Stephens		9/19/2022	9/19/2022
3 additional Officers and Directors records available in full report.

General Information

Outstanding Shares:	128,500,001	(As of 12/31/2023)
Shareholders:	787
Stock Exchange:	ASX

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN